Cancer gene therapy: an awkward adolescence
- 30 June 2003
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 10 (7) , 501-508
- https://doi.org/10.1038/sj.cgt.7700602
Abstract
At the Eleventh International Conference on Gene Therapy of Cancer (December 12–14, 2002, San Diego, CA) progress on using gene transfer technology to treat cancer was presented. Although there is as yet no cancer gene therapy being marketed, considerable progress has been made in defining likely strategies and likely targets for gene therapy of cancer. These strategies, including viral and non-viral delivery systems, and potential targets in cancer cells linked to our developing knowledge of cancer cell biology, are reviewed in this paper. Use of gene therapy to sensitize tumors to radiation and chemotherapy is one promising area of investigation. Some of the ancillary benefits of research on cancer gene therapy, including the development of public-private partnerships, recruitment of laboratory scientists into clinical research, and credentialing of potential cancer cell targets for therapies other than gene therapy, are noted.Keywords
This publication has 37 references indexed in Scilit:
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancerCancer Gene Therapy, 2002
- TNFerade Biologic: Preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha geneCancer Gene Therapy, 2002
- Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunityCancer Gene Therapy, 2002
- Transcription-targeted gene therapy for androgen-independent prostate cancerCancer Gene Therapy, 2002
- Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell linesCancer Gene Therapy, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- Development of lentiviral vectors for antiangiogenic gene deliveryCancer Gene Therapy, 2001
- Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cellsCancer Gene Therapy, 2000
- The Hallmarks of CancerCell, 2000